Zura Bio Ltd 8-K

What Happened

• Zura Bio Ltd (ZURA) held its Annual General Meeting on June 17, 2026. Shareholders approved an Amended and Restated 2023 Equity Incentive Plan, which became effective immediately upon approval. The board had previously approved the amendment on April 23, 2026, subject to shareholder consent.
• Shareholders also elected eight director nominees to the Board and ratified WithumSmith+Brown, PC as the company’s independent registered public accounting firm for fiscal year 2026.

Key Details

• Amended 2023 Equity Incentive Plan: Approved with votes — For: 38,850,373; Against: 17,403,607; Abstain: 26,663; Broker Non‑Votes: 18,267,509.
• Director elections (votes For / Against / Abstain):
  • Daniel Becker: 55,968,512 / 291,173 / 20,958
  • Mark Eisner: 56,209,068 / 49,466 / 22,109
  • Jennifer Jarrett: 39,788,639 / 16,471,044 / 20,958
  • Sandeep Kulkarni: 56,250,391 / 8,292 / 21,960
  • Amit Munshi: 40,229,829 / 16,027,697 / 23,115
  • Ajay Nirula: 56,249,212 / 8,319 / 23,113
  • Steven Schoch: 56,197,526 / 61,025 / 22,093
  • Parvinder Thiara: 55,766,669 / 490,857 / 23,115
• Auditor ratification: WithumSmith+Brown, PC ratified with votes — For: 74,323,697; Against: 30,527; Abstain: 193,928.
• The Amended 2023 Plan text is attached as Exhibit 10.1 to the 8-K (filed June 18, 2026).

Why It Matters

• Approval of the amended equity incentive plan gives Zura Bio formal authority to grant stock-based compensation to employees, directors and consultants — a key tool for hiring, retention and aligning stakeholders, but one that can increase share count (potential dilution).
• The director election results show generally strong support for most nominees, though several candidates received relatively large opposing votes, which investors may monitor as an indicator of shareholder sentiment.
• Ratifying the auditor ensures continuity of external financial oversight for FY2026.